The field of cancer research has increasingly focused on the intricate interplay between regulated cell death (RCD) pathways and the immune microenvironment in tumor progression and treatment. Regulated cell death, encompassing processes such as ferroptosis, curroptosis, and pan-apoptosis, plays a pivotal role in organismal development and disease pathogenesis. Recent studies have highlighted the significance of these cell death mechanisms in tumorigenesis, suggesting their potential as therapeutic targets. Ferroptosis, characterized by iron-dependent phospholipid peroxidation, is particularly relevant in treatment-resistant cancer cells, which are often in a stromal state and prone to metastasis. Curroptosis, a copper- and mitochondria-dependent cell death mechanism, and pan-apoptosis, mediated by the PANoptosome complex, further expand the landscape of RCD. Despite these advances, the precise mechanisms by which these pathways influence the tumor immune microenvironment remain inadequately understood, necessitating further investigation to harness their therapeutic potential.
This research topic aims to explore the effects of emerging regulatory cell death modes on tumor disease development and progression, with a focus on remodeling the tumor immune microenvironment. By examining the crosstalk between tumor progression and treatment through the lens of ferroptosis, curroptosis, and pan-apoptosis, the research seeks to uncover novel therapeutic strategies that can beneficially impact neoplastic diseases. Key objectives include identifying biomarkers and mechanisms of these RCD pathways, understanding their complex effects on the immune microenvironment, and evaluating potential novel drugs and nanoparticles that modulate these processes.
To gather further insights into the crosstalk between emerging cell death pathways and immune microenvironment remodeling in cancer, we welcome articles addressing, but not limited to, the following themes:
- Biomarkers and mechanisms of curroptosis, ferroptosis, or pan-apoptosis in inflammatory diseases.
- Complex effects of emerging forms of tumor cell death on the immune microenvironment, as well as the regulated death of other cells in the immune microenvironment that affect tumor biology.
- Combination study of the crosstalk effects of curroptosis, ferroptosis, and pan-apoptosis in tumor progression and treatment.
- The potential novel drugs and nanoparticles to induce or inhibit new RCD pathways and their therapeutic effects on cancer.
- Effects of modulating RCD processes on cancer drug resistance.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The field of cancer research has increasingly focused on the intricate interplay between regulated cell death (RCD) pathways and the immune microenvironment in tumor progression and treatment. Regulated cell death, encompassing processes such as ferroptosis, curroptosis, and pan-apoptosis, plays a pivotal role in organismal development and disease pathogenesis. Recent studies have highlighted the significance of these cell death mechanisms in tumorigenesis, suggesting their potential as therapeutic targets. Ferroptosis, characterized by iron-dependent phospholipid peroxidation, is particularly relevant in treatment-resistant cancer cells, which are often in a stromal state and prone to metastasis. Curroptosis, a copper- and mitochondria-dependent cell death mechanism, and pan-apoptosis, mediated by the PANoptosome complex, further expand the landscape of RCD. Despite these advances, the precise mechanisms by which these pathways influence the tumor immune microenvironment remain inadequately understood, necessitating further investigation to harness their therapeutic potential.
This research topic aims to explore the effects of emerging regulatory cell death modes on tumor disease development and progression, with a focus on remodeling the tumor immune microenvironment. By examining the crosstalk between tumor progression and treatment through the lens of ferroptosis, curroptosis, and pan-apoptosis, the research seeks to uncover novel therapeutic strategies that can beneficially impact neoplastic diseases. Key objectives include identifying biomarkers and mechanisms of these RCD pathways, understanding their complex effects on the immune microenvironment, and evaluating potential novel drugs and nanoparticles that modulate these processes.
To gather further insights into the crosstalk between emerging cell death pathways and immune microenvironment remodeling in cancer, we welcome articles addressing, but not limited to, the following themes:
- Biomarkers and mechanisms of curroptosis, ferroptosis, or pan-apoptosis in inflammatory diseases.
- Complex effects of emerging forms of tumor cell death on the immune microenvironment, as well as the regulated death of other cells in the immune microenvironment that affect tumor biology.
- Combination study of the crosstalk effects of curroptosis, ferroptosis, and pan-apoptosis in tumor progression and treatment.
- The potential novel drugs and nanoparticles to induce or inhibit new RCD pathways and their therapeutic effects on cancer.
- Effects of modulating RCD processes on cancer drug resistance.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.